Inhibrx Biosciences (INBX) Return on Equity (2024 - 2025)
Inhibrx Biosciences (INBX) reported Return on Equity of 0.06% for Q4 2025, down 17.0% year-over-year from 0.08% in Q4 2024, and down 112.33% quarter-over-quarter from 0.03% in Q3 2025.
Inhibrx Biosciences (INBX) Return on Equity (2024 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 2 years of Return on Equity data on file, last reported at 0.06% in Q4 2025.
- Return on Equity for Q4 2025 came in at 0.06%, down 17.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.06% (down 17.0% YoY), and the FY2025 annual result was 0.02%, down 21.0% from the prior year.
- Return on Equity retreated to 0.06% in Q4 2025 per INBX's latest filing, from 0.03% in the prior quarter.
- Over five years, Return on Equity peaked at 0.15% in Q1 2025 and troughed at 0.1% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -0.81% |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -0.04% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.00% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -0.01% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.01% |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | -0.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.06% |
| Sep 30, 2025 | -0.03% |
| Jun 30, 2025 | -0.02% |
| Mar 31, 2025 | 0.15% |
| Dec 31, 2024 | 0.11% |
| Sep 30, 2024 | 0.08% |
| Jun 30, 2024 | 0.14% |
| Mar 31, 2024 | -0.10% |